UniQure shares surged over 20% after Wells Fargo and RBC upgraded the stock, citing improving regulatory prospects for its Huntington disease gene therapy AMT-130. Analysts said the expected departure of a key FDA official could reopen discussions on the therapy approval, boosting investor optimism.